Genetic evaluation of the effect of GLCCI1 rs37973 and FKBP5 rs4713916 on the response to corticosteroids in COPD patients

Although inhaled glucocorticoids (ICS) are highly effective in asthma, they provide much less clinical benefit in COPD, with only 10% of COPD patients showing clinical response. The variability of response to treatment with ICS may be related to genetic variations. Furthermore, various single-nucleotide polymorphisms (SNPs) have been identified in the glucocorticoid-induced transcript 1 (GLCCI1) gene and the related co-chaperone FKBP5 gene. The aim of our study was to investigate whether common variants of the aforementioned genes are associated with COPD phenotypes, lung function and ICS efficacy.